Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Recruiting · NCT06876844 · Registry updated 2025-03-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC | Head and Neck Neoplasms, Neoplasms by Site, head and neck cancer, neoplasm | Recruiting | Phase 2 | 2025-03-14 | NCT06876844 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 77 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Shanghai | China | 1 |